Niosomal tannic acid drug delivery system: An efficient strategy against vancomycin-intermediate Staphylococcus aureus (VISA) infections

Document Type : Research Paper

Authors

1 Department of Microbiology, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

2 Department of Bacteriology, Pasteur Institute of Iran, Tehran, Iran

3 Department of NanoBiotechnology, Pasteur Institute of Iran, Tehran, Iran

4 Department of Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran

5 Anatomy Department, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran

6 Infectious Disease Research Center, Hamadan University of Medical Sciences, Hamadan, Iran

Abstract

Objective(s): Our study aimed to formulate a niosomal system for enhancing tannic acid’s antibacterial and antibiofilm activities against vancomycin-intermediate staphylococcus aureus (VISA). 
Materials and Methods: Niosomal tannic acid was formulated by the thin-film hydration technique, which their physicochemical attributes, including drug loading, particle size, zeta potential, morphology, encapsulation efficiency (EE%), polydispersity index (PDI), release profile, were evaluated. To investigate the cell viability of the prepared niosomes, the cytotoxicity effect was analyzed against the human foreskin fibroblast (HFF) cell line. Finally, the antibacterial and anti-biofilm activities of niosomal formulation were examined against VISA strains and compared tothe free drug.
Results: Scanning electron microscopy images showed that the niosomal formulation incorporated tannic acid was homogeneous, spherical, and identical in size (151.9 nm). EE% and surface charge of the synthesized niosomes were 68.90% and -60 mV, respectively. The tannic acid-encapsulated niosomes showed a significant antibacterial potential in comparison with the free drug. Furthermore, niosomal tannic acid reduced the biofilm formation ability in all VISA strains and efficiently eradicated the formed bacterial biofilms at the same concentrations of the free drug.
Conclusion: Niosomes, as vesicular-based nanoparticles, are known to be potent drug delivery vehicles due to numerous features such as non-toxicity, small size, sustained-release profile, and protection from pharmaceutical degradation. Niosomes have a high capacity to deliver wide range of antimicrobial agents, including natural compounds, which could be presented as a novel approach against bacterial infections, particularly VISA strains.
Objective(s): Our study aimed to formulate a niosomal system for enhancing tannic acid’s antibacterial and antibiofilm activities against vancomycin-intermediate staphylococcus aureus (VISA). 
Materials and Methods: Niosomal tannic acid was formulated by the thin-film hydration technique, which their physicochemical attributes, including drug loading, particle size, zeta potential, morphology, encapsulation efficiency (EE%), polydispersity index (PDI), release profile, were evaluated. To investigate the cell viability of the prepared niosomes, the cytotoxicity effect was analyzed against the human foreskin fibroblast (HFF) cell line. Finally, the antibacterial and anti-biofilm activities of niosomal formulation were examined against VISA strains and compared tothe free drug.
Results: Scanning electron microscopy images showed that the niosomal formulation incorporated tannic acid was homogeneous, spherical, and identical in size (151.9 nm). EE% and surface charge of the synthesized niosomes were 68.90% and -60 mV, respectively. The tannic acid-encapsulated niosomes showed a significant antibacterial potential in comparison with the free drug. Furthermore, niosomal tannic acid reduced the biofilm formation ability in all VISA strains and efficiently eradicated the formed bacterial biofilms at the same concentrations of the free drug.
Conclusion: Niosomes, as vesicular-based nanoparticles, are known to be potent drug delivery vehicles due to numerous features such as non-toxicity, small size, sustained-release profile, and protection from pharmaceutical degradation. Niosomes have a high capacity to deliver wide range of antimicrobial agents, including natural compounds, which could be presented as a novel approach against bacterial infections, particularly VISA strains.
 

Keywords

References

1.    Kyaw MH, Kern DM, Zhou S, Tunceli O, Jafri HS, Falloon J. Healthcare utilization and costs associated with S. aureus and P. aeruginosa pneumonia in the intensive care unit: a retrospective observational cohort study in a US claims database. BMC Health Serv Res. 2015;15(1):241.
2.    Nasaj M, Farmany A, Shokoohizadeh L, Jalilian FA, Mahjoub R, Roshanaei G, et al. Development of Chitosan-Assisted Fe 3 O 4@ SiO 2 Magnetic Nanostructures Functionalized with Nisin as a Topical Combating System against Vancomycin-Intermediate Staphylococcus aureus (VISA) Skin Wound Infection in Mice. J Nanomater. 2022;2022:1-17.
3.    Wady AF, Machado AL, Foggi CC, Zamperini CA, Zucolotto V, Moffa EB, et al. Effect of a Silver Nanoparticles Solution on Staphylococcus aureus and Candida spp. J Nanomater. 2014;2014:1-7.
4.    Zhao G HC, Xue Y. In vitro evaluation of chitosan‐coated liposome containing both coenzyme Q10 and alpha‐lipoic acid: Cytotoxicity, antioxidant activity, and antimicrobial activity. J Cosmet Dermatol. 2018;17(2):258-262.
5.    Durymanov M KT, Lehmann SE, Reineke J. Exploiting passive nanomedicine accumulation at sites of enhanced vascular permeability for non-cancerous applications. J Control Release. 2017 Sep;261:10-22.
6.    Jawad KH, Marzoog TR, Hasoon BA, Sulaiman GM, Jabir MS, Ahmed EM, et al. Antibacterial activity of bismuth oxide nanoparticles compared to amikacin against Acinetobacter baumannii and Staphylococcus aureus. J Nanomater. 2022;2022:1-11.
7.    Zhu X, Liu C, Gao S, Lu Y, Chen Z, Sun Z. Vancomycin intermediate-resistant Staphylococcus aureus (VISA) isolated from a patient who never received vancomycin treatment. Int J Infect Dis. 2015;33:185-190.
8.    Kranjec C, Morales Angeles D, Torrissen Mårli M, Fernández L, García P, Kjos M, et al. Staphylococcal biofilms: Challenges and novel therapeutic perspectives. Antibiotics. 2021;10(2):131.
9.    Kakoullis L, Papachristodoulou E, Chra P, Panos G. Mechanisms of antibiotic resistance in important gram-positive and gram-negative pathogens and novel antibiotic solutions. Antibiotics. 2021;10(4):415.
10.    Raeiszadeh M, Pardakhty A, Sharififar F, Farsinejad A, Mehrabani M, Hosseini-Nave H, et al. Development, physicochemical characterization, and antimicrobial evaluation of niosomal myrtle essential oil. Res Pharm Sci. 2018;13(3):250-261.
11.    Rezaeiroshan A, Saeedi M, Morteza-Semnani K, Akbari J, Hedayatizadeh-Omran A, Goli H, et al. Vesicular formation of trans-ferulic acid: an efficient approach to improve the radical scavenging and antimicrobial properties. J Pharm Innov. 2022:1-10.
12.    Pardakhty A, Moazeni E. Nano-niosomes in drug, vaccine and gene delivery: a rapid overview. Nanomed J. 2013;1(1):1-12.
13.    Lee MK. Liposomes for Enhanced Bioavailability of Water-Insoluble Drugs: In Vivo Evidence and Recent Approaches. Pharmaceutics. 2020;12(3):264.
14.    Kumar GP, Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery—an overview. Acta pharmaceutica sinica B. 2011;1(4):208-219.
15.    Jain S, Jain V, Mahajan S. Lipid based vesicular drug delivery systems. Adv Pharmacol Sci 2014;2014:1-12.
16.    Aelenei N, Popa MI, Novac O, Lisa G, Balaita L. Tannic acid incorporation in chitosan-based microparticles and in vitro controlled release. J Mater Sci Mater Med 2009;20:1095-1102.
17.    Dabbaghi A, Kabiri K, Ramazani A, Zohuriaan‐Mehr MJ, Jahandideh A. Synthesis of bio‐based internal and external cross‐linkers based on tannic acid for preparation of antibacterial superabsorbents. Polym Adv Technol. 2019;30(11):2894-2905.
18.    Lau S, Wahn J, Schulz G, Sommerfeld C, Wahn U. Placebo‐controlled study of the mite allergen‐reducing effect of tannic acid plus benzyl benzoate on carpets in homes of children with house dust mite sensitization and asthma. Pediatr Allergy Immunol. 2002;13(1):31-36.
19.    Nonaka G-i, Nishioka I, Nishizawa M, Yamagishi T, Kashiwada Y, Dutschman GE, et al. Anti-AIDS agents, 2: inhibitory effect of tannins on HIV reverse transcriptase and HIV replication in H9 lymphocyte cells. J Nat Prod. 1990;53(3):587-595.
20.    Kaczmarek B. Tannic acid with antiviral and antibacterial activity as a promising component of biomaterials—A minireview. Materials. 2020;13(14):3224.
21.    Funatogawa K, Hayashi S, Shimomura H, Yoshida T, Hatano T, Ito H, et al. Antibacterial activity of hydrolyzable tannins derived from medicinal plants against Helicobacter pylori. Microbiol and immunol. 2004;48(4):251-261.
22.    Chung KT, Jr SS, Lin WF, Wei C. Growth inhibition of selected food‐borne bacteria by tannic acid, propyl gallate and related compounds. Lett Appl Microbiol. 1993;17(1):29-32.
23.    Kyaw BM, Arora S, Lim CS. Anti-Pseudomonal and anti-biofilm activity of tannic acid in combination with antibiotics. Inter J Integr Biol. 2011;11(3):110.
24.    Belhaoues S, Amri S, Bensouilah M. Major phenolic compounds, antioxidant and antibacterial activities of Anthemis praecox Link aerial parts. S Afr J Bot. 2020;131:200-205.
25.    Akiyama H, Fujii K, Yamasaki O, Oono T, Iwatsuki K. Antibacterial action of several tannins against Staphylococcus aureus. J Antimicrob Chemother. 2001;48(4):487-491.
26.    Mehrarya M, Gharehchelou B, Haghighi Poodeh S, Jamshidifar E, Karimifard S, Farasati Far B, et al. Niosomal formulation for antibacterial applications. J Drug Target. 2022;30(5):476-943.
27.    Ghafelehbashi R, Akbarzadeh I, Tavakkoli Yaraki M, Lajevardi A, Fatemizadeh M, Heidarpoor Saremi L. Preparation, physicochemical properties, in vitro evaluation and release behavior of cephalexin-loaded niosomes. Int J Pharm. 2019;569:118580.
28.    Hemmati J, Chegini Z, Arabestani MR. Niosomal-based drug delivery platforms: A promising therapeutic approach to fight Staphylococcus aureus drug resistance. J Nanomater. 2023;2023:1-18.
29.    Del AK, Kaboosi H, Jamalli A, Ghadikolaii FP. Prevalence and expression of PSM a gene in biofilm-producing Staphylococcus aureus clinical isolates. Jundishapur J Microbiol. 2019;12(8):e89610.
30.    Khan R, Irchhaiya R. Niosomes: a potential tool for novel drug delivery. J pharm investig. 2016;46:195-204.
31.    Zafari M, Adibi M, Chiani M, Bolourchi N, Barzi SM, Nosrati MSS, et al. Effects of cefazolin-containing niosome nanoparticles against methicillin-resistant Staphylococcus aureus biofilm formed on chronic wounds. Biomed Mater. 2021;16(3):035001.
32.    Moazeni E, Gilani K, Sotoudegan F, Pardakhty A, Najafabadi AR, Ghalandari R, et al. Formulation and in vitro evaluation of ciprofloxacin containing niosomes for pulmonary delivery. J Microencapsul. 2010;27(7):618-627.
33.    WS R. Imagej, us national institutes of health, bethesda, maryland, usa. http://imagej nih gov/ij/. 2011.
34.    Heidari F, Akbarzadeh I, Nourouzian D, Mirzaie A, Bakhshandeh H. Optimization and characterization of tannic acid loaded niosomes for enhanced antibacterial and anti-biofilm activities. Adv Powder Technol. 2020;31(12):4768-4781.
35.    Blainski A, Lopes GC, De Mello JCP. Application and analysis of the folin ciocalteu method for the determination of the total phenolic content from Limonium brasiliense L. Molecules. 2013;18(6):6852-6865.
36.    Sahiner N, Sagbas S, Aktas N, Silan C. Inherently antioxidant and antimicrobial tannic acid release from poly (tannic acid) nanoparticles with controllable degradability. Colloids Surf B 2016;142:334-343.
37.    Ali H, Shirode AB, Sylvester PW, Nazzal S. Preparation, characterization, and anticancer effects of simvastatin–tocotrienol lipid nanoparticles. Int J Pharm. 2010;389(1-2):223-231.
38.    Thornsberry C. Antimicrobial susceptibility testing of anaerobic bacteria: review and update on the role of the National Committee for Clinical Laboratory Standards. Rev infect dis. 1990;1(12):218-222.
39.    Barani M, Mirzaei M, Torkzadeh-Mahani M, Adeli-Sardou M. Evaluation of carum-loaded niosomes on breast cancer cells: Physicochemical properties, in vitro cytotoxicity, flow cytometric, DNA fragmentation and cell migration assay. Sci Rep. 2019;9(1):7139.
40.    Mirzaei R, Alikhani MY, Arciola CR, Sedighi I, Yousefimashouf R, Bagheri KP. Prevention, inhibition, and degradation effects of melittin alone and in combination with vancomycin and rifampin against strong biofilm producer strains of methicillin-resistant Staphylococcus epidermidis. Biomed Pharmacother. 2022;147:112670.
41.    Aires-de-Sousa M. Methicillin-resistant Staphylococcus aureus among animals: Current overview. Clin Microbiol Infect. 2017;23(6):373-380.
42.    Awate PS, Pimple TP, Pananchery JF, Jain AS. Formulation and evaluation of berberine hcl as niosomal drug delivery system. Asian J Pharm Res. 2020;10(3):149-159.
43.    Shadvar P, Mirzaie A, Yazdani S. Fabrication and optimization of amoxicillin-loaded niosomes: an appropriate strategy to increase antimicrobial and anti-biofilm effects against multidrug-resistant Staphylococcus aureus strains. Drug Dev Ind Pharm. 2021;47(10):1568-1577.
44.    Dwivedi A, Mazumder A, Nasongkla N. Layer-by-layer nanocoating of antibacterial niosome on orthopedic implant. Int J Pharm. 2018;547(1-2):235-243.
45.    Satish J, Amusa AS, Gopalakrishna P. In vitro activities of fluoroquinolones entrapped in non-ionic surfactant vesicles against ciprofloxacin-resistant bacteria strains. J Pharm Technol Drug Res. 2012;1:5.
46.    Stan D, Enciu A-M, Mateescu AL, Ion AC, Brezeanu AC, Stan D, et al. Natural compounds with antimicrobial and antiviral effect and nanocarriers used for their transportation. Front Pharmacol. 2021;12:723233.
47.    Shishir MRI, Taip FS, Saifullah M, Aziz NA, Talib RA. Effect of packaging materials and storage temperature on the retention of physicochemical properties of vacuum packed pink guava powder. Food Packag Shelf Life 2017;12:83-90.
48.    Shishir MRI, Xie L, Sun C, Zheng X, Chen W. Advances in micro and nano-encapsulation of bioactive compounds using biopolymer and lipid-based transporters. Trends Food Sci Technol. 2018;78:34-60.
49.    Tabatabai MB, Mirjalili M, Yazdiyan F, Hekmatimoghaddam S. Antibacterial activity and cytotoxicity of nanoliposomic and nanoniosomic essential oil of Trachyspermum copticum. Proc Natl Acad Sci India Sect B Biol Sci. 2019;89(3):1109-1116.
50.    Yadav, G. and Jain, A. 112 Design and development of tea tree oil niosomal gel for bacterial infection. J Pharm Chem. 2022;18(1):1.
51.    Patel J, Ketkar S, Patil S, Fearnley J, Mahadik KR, Paradkar AR. Potentiating antimicrobial efficacy of propolis through niosomal-based system for administration. Integr Med Res. 2015;4(2):94-101.
52.    Najafloo R, Baheiraei N, Imani R. Synthesis and characterization of collagen/calcium phosphate scaffolds incorporating antibacterial agent for bone tissue engineering application. J Bioact Compat Polym. 2021;36(1):29-43.
53.    Gugleva V, Michailova V, Mihaylova R, Momekov G, Zaharieva MM, Najdenski H, et al. Formulation and Evaluation of Hybrid Niosomal In Situ Gel for Intravesical Co-Delivery of Curcumin and Gentamicin Sulfate. Pharmaceutics. 2022;14(4):747.
54.    Satish J, Amusa AS, Gopalakrishna P. In vitro activities of fluoroquinolones entrapped in non-ionic surfactant vesicles against ciprofloxacin-resistant bacteria strains. J Pharm Technol Drug Res. 2012;1(1):1-11.
55.    Huang C-M, Chen C-H, Pornpattananangkul D, Zhang L, Chan M, Hsieh M-F, et al. Eradication of drug resistant Staphylococcus aureus by liposomal oleic acids. Biomaterials. 2011;32(1):214-221.
56.    Kopermsub P, Mayen V, Warin C. Potential use of niosomes for encapsulation of nisin and EDTA and their antibacterial activity enhancement. Food Res Int. 2011;44(2):605-612.
57.    Furneri PM, Fresta M, Puglisi G, Tempera G. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob Agents Chemother. 2000;44(9):2458-2464.
58.    Stepanović S, Vuković D, Dakić I, Savić B, Švabić-Vlahović M. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J Microbiol Methods. 2000;40(2):175-179.
59.    Arciola CR, Campoccia D, Speziale P, Montanaro L, Costerton JW. Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. Biomaterials. 2012;33(26):5967-582.
60.    Barakat HS, Kassem MA, El-Khordagui LK, Khalafallah NM. Vancomycin-eluting niosomes: a new approach to the inhibition of staphylococcal biofilm on abiotic surfaces. AAPS Pharm Sci Tech. 2014;15:1263-1274.
61.    Nejadnik MR, van der Mei HC, Norde W, Busscher HJ. Bacterial adhesion and growth on a polymer brush-coating. Biomaterials. 2008;29(30):4117-4121.
62.    Banerjee I, Pangule RC, Kane RS. Antifouling coatings: recent developments in the design of surfaces that prevent fouling by proteins, bacteria, and marine organisms. Adv Mater. 2011;23(6):690-718.
63.    Francolini I, Donelli G. Prevention and control of biofilm-based medical-device-related infections. FEMS Immunol Med Microbiol. 2010;59(3):227-328.
64.    Neopane P, Nepal HP, Shrestha R, Uehara O, Abiko Y. In vitro biofilm formation by Staphylococcus aureus isolated from wounds of hospital-admitted patients and their association with antimicrobial resistance. Int J Gen Med. 2018;18(1):25-32.
65.    Kashef MT, Saleh NM, Assar NH, Ramadan MA. The antimicrobial activity of ciprofloxacin-loaded niosomes against ciprofloxacin-resistant and biofilm-forming Staphylococcus aureus. Infect Drug Resist. 2020;1(8):1619-1629.
66.    Soltani M, Hajikhani B, Zamani S, Haghighi M, Hashemi A, Nasiri MJ, Dadashi M, Pourhossein B, Goudarzi M. Molecular characterization of Staphylococcus aureus strains isolated from hospitalized patients based on coagulase gene polymorphism analysis: High frequency of vancomycin-intermediate S. aureus and the emergence of coagulase type II in Iran. Gene Rep.2021;1(23):101078.
67.    Hemmati J, Azizi M, Asghari B, Arabestani MR. Multidrug-Resistant Pathogens in Burn Wound, Prevention, Diagnosis, and Therapeutic Approaches (Conventional Antimicrobials and Nanoparticles). Can J Infect Dis Med Microbiol. 2023;2023:2023:8854311.
Nanomedicine Journal
Volume 11, Issue 3
July 2024
Pages 320-331

Files

Share

How to cite

Statistics